98P Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)
Titel:
98P Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)
Auteur:
Xu, C. Chen, Q. Zhou, C. Wu, L. Li, W. Zhang, H. Li, Y. Xu, F. Xiong, J. Wang, Q. Zhang, H. Jiang, Y. Yin, H. Wu, Q. Dai, Q. Hu, J. Chen, J. Zhang, J. Wu, G. Wu, Y-L.